Atai Life Sciences N.V. (ATAI) Stock Price, Quote & News

Company Profile

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial...

Industry: Biotechnology

Sector: Healthcare

Phone: 332 282 0507

Website: www.ataibeckley.com

Address:

250 West 34th Street, New York, United States

matrixtrade123 Jul. 19 at 2:34 PM

$ATAI follow the Yellow Brick Road __ I wonder how much Rob Conley former Chief Science Officer at Eli Lilly had in this deal? Frbom my understanding this deal does not happen overnight but takes months to finalize. ATAI Life Science could have been advised to buy Beckley Psytech by Eli Lilly and other insiders of the 3 companies. Robert Conley, M.D. Chief Research and Development Officer Rob became Chief Research and Development Officer of AtaiBeckley in 2025 and was previously the Chief Scientific and Medical Officer at Beckley Psytech. He has served as Senior Vice President at Eleusis and Chief Science Officer, Neuroscience at Eli Lilly and Co.

0 · Reply

Horseman23 Jul. 19 at 1:48 PM

$ATAI still bullish for the sector - 9.25/share with high potential, thats like a 100% increase from a month ago

1 · Reply

Arthur_PL Jul. 19 at 11:24 AM

$ATAI It turns out I was right — and we found out quite quickly. I only wish the story had ended at a higher valuation. Still, I did very well on ATAI, having bought at an average price of around $1.40, perhaps even lower. I have already sold my entire position and reinvested the proceeds in several new, very interesting companies, including biotech names. After years in the market, I have learned to treat both gains and losses calmly. Excessive expectations often lead only to frustration. The stock market is not the right place to invest your emotions.

2 · Reply

Boldrake Jul. 19 at 10:26 AM

$ATAI time is a gentleman, we will get to know what had happened here suddenly. Thus in the meantime I will not invest not even a penny in any of the stocks owned and or led by this gentleman. He lost credibility and loyanty. Not that here we are in a no profit business but at least there are other companies who you know who they are

0 · Reply

Boldrake Jul. 19 at 10:12 AM

$ATAI well, explain me the rationale of this chart. IPO at 18$ in 2021; I believe there are still many who invested for the long run onboard. How many have been betrayed. I understand business is business but what he eas telling every single tine was that he was running for the long term. Still why talking about a 30BL market potential and put it on sale basically gifting the company to Lilly. As a conseguence killing all other companies in the sector that now should compete against Lilly. I start to think ATAI bad nothing on their hands and Lilly is just the one that will defenetily close down this business

0 · Reply

leLu83 Jul. 19 at 1:19 AM

$ATAI food for thought...the macro market is in peril and could effect small cap pre revenue stocks substantially. With great access by managment and board to administration, maybe we see the smoke before the fires. Having massive dry powder to scoop on discounted high quality equities is exactly the recipe for outsized gains 💯

0 · Reply

KG_Macro Jul. 18 at 4:41 PM

$ATAI Atai CEO in July 2025 , in announcing Ferring investment: (referring to Ferring having a) "deep understanding of commercialization, market dynamics, and how to build and run effective sales teams is invaluable for atai as it prepares to transform from a clinical-stage biotech into a fully integrated commercial company over time".

0 · Reply

twiggs462 Jul. 18 at 2:54 PM

I personally think $ATAI sold becuase they know that cannot compete with $DFTX or $CMPS short term. Those two are going to take the spotlight and investors and $ATAI would have run out of money. I bet $LLY will take BPL-003 to market, but $ATAI would have not been able to

2 · Reply

KG_Macro Jul. 18 at 1:36 PM

$ATAI The spin from the CEO about selling out is now the importance of getting these valuable meds to patients as quick as possible (he doesn't convenientlymention getting his $30+ million as soon as possible or CA his $500+ mil) . Ok, but isnt that what we were told repeatedly that Ferring was for when they invested? An experienced European Pharma partner to commercialize the assets? Oh well, I hope the deal fails or is sweetened but now that I know what lying scoundrals these guys are I think I'll probably be relieved to be moving on.

1 · Reply

TimeTaEat Jul. 18 at 1:35 PM

$ATAI I'm not saying this is the ONLY factor behind $ATAI's recent price action… there are always multiple forces at work. But one thing people overlook is this: Today's resistance can simply be yesterday's winners taking profits. Every share sold has to be absorbed by a buyer. Once that supply starts drying up, resistance often weakens. Nothing is guaranteed, but if demand stays strong after that selling pressure is absorbed, the path to $7.50+ can become a lot less crowded. I have 295 $7 calls and expect slightly more upside in the next few weeks.

1 · Reply

AtaiBeckley downgraded to Hold from Buy at TD Cowen

2026-07-17T11:10:24.000Z - 2 days ago

Helus Pharma price target lowered to $45 from $48 at Guggenheim

GHRS HELP LLY

2026-07-16T22:20:14.000Z - 2 days ago

AtaiBeckley downgraded to Hold from Buy at Jefferies

2026-07-16T20:20:19.000Z - 2 days ago

AtaiBeckley downgraded to Hold from Buy at JonesResearch

CMPS DFTX GHRS HELP

2026-07-16T19:00:14.000Z - 2 days ago

AtaiBeckley downgraded to Hold from Buy at Canaccord

2026-07-16T18:15:11.000Z - 2 days ago

AtaiBeckley downgraded to Neutral from Buy at Guggenheim

Jul 16, 2026, 1:58 PM EDT - 2 days ago

AtaiBeckley stock is soaring, and it has Eli Lilly to thank

LLY

2026-07-16T16:55:17.000Z - 2 days ago

AtaiBeckley downgraded to Hold from Buy at Maxim

2026-07-16T16:05:28.000Z - 2 days ago

AtaiBeckley rises 32.9%

2026-07-16T16:00:12.000Z - 2 days ago

AtaiBeckley downgraded to Neutral from Overweight at Cantor Fitzgerald

2026-07-16T14:50:51.000Z - 2 days ago

Why Is AtaiBeckley N.V. (ATAI) Stock Up Today?

LLY

Jul 16, 2026, 10:26 AM EDT - 3 days ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AtaiBeckley Inc. (Nasdaq – ATAI), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)

NUVL

Jul 16, 2026, 10:23 AM EDT - 3 days ago

Lilly Buys Psychedelic Drugmaker AtaiBeckley for $3.8 Billion

LLY

2026-07-16T14:06:35.000Z - 3 days ago